Stocks and Investing
Stocks and Investing
Thu, September 14, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, September 13, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gregory Renza Reiterated (SPRB) at Buy and Held Target at $8 on, Sep 13th, 2023
Gregory Renza of RBC Capital, Reiterated "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $8 on, Sep 13th, 2023.
Gregory has made no other calls on SPRB in the last 4 months.
There are 4 other peers that have a rating on SPRB. Out of the 4 peers that are also analyzing SPRB, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Gregory
- Joseph Schwartz of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $9 on, Friday, September 8th, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $7 on, Friday, August 18th, 2023
- Jonathan Wolleben of "JMP Securities" Maintained at Buy with Increased Target to $8 on, Wednesday, August 16th, 2023
- Tiago Fauth of "Credit Suisse" Reiterated at Buy and Held Target at $4 on, Tuesday, May 16th, 2023
Contributing Sources